• P-ISSN 0973-7200 E-ISSN 2454-8405
  • Follow us

Journal of Pharmaceutical Research

Article

Combining Multi-kinase Inhibitors and Immune Checkpoints Blockade in Hepatocellular Carcinoma: A Pharmacotherapeutic Approach
  • VIEWS 366
  • PDF 68

Journal of Pharmaceutical Research

DOI: 10.18579/jopcr/v23.3.75

Year: 2024, Volume: 23, Issue: 3, Pages: 141-147

Review Article

Combining Multi-kinase Inhibitors and Immune Checkpoints Blockade in Hepatocellular Carcinoma: A Pharmacotherapeutic Approach

Vothani Sarath Babu1,∗, P Bhavana Sree2, C Pallavi3, S Pavithra2, P M Vasanth2

1Faculty, Department of Pharmaceutics, S V U College of Pharmaceutical Sciences, Sri Venkateswara University, Tirupati, 517502, Andhra Pradesh, India
2S V U College of Pharmaceutical Sciences, Sri Venkateswara University, Tirupati, 517502, Andhra Pradesh, India
3Department of Biochemistry, S V U College of Sciences, S V U College of Pharmaceutical Sciences, Sri Venkateswara University, Tirupati, 517502, Andhra Pradesh, India

*Corresponding author email: [email protected]

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Liver cancer, particularly hepatocellular carcinoma (HCC), represents a significant global health burden with limited treatment options and poor prognosis. This article provides a comprehensive overview of pharmacotherapy for liver cancer, focusing on both established and emerging drugs. Current standard-of-care treatments, including sorafenib and lenvatinib, target key pathways involved in tumor growth and angiogenesis. However, their efficacy is often limited, prompting ongoing research into novel therapeutic approaches. Emerging immunotherapies, such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, have shown promise in clinical trials, offering new avenues for personalized treatment strategies. Additionally, targeted therapies aimed at specific genetic alterations, such as FGFR inhibitors for FGFR-altered HCC, demonstrate potential for improved outcomes in select patient populations. These abstract highlights the evolving landscape of pharmacotherapy for liver cancer and underscores the need for further research to optimize treatment efficacy and patient outcomes.

Keywords

Multi­kinase Inhibitors, Immune Checkpoint Inhibitors, Hepatocellular Carcinoma (HCC), Sorafenib

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394–424. Available from: https://doi.org/10.3322/caac.21492
  2. Petrick JL, Florio AA, Znaor A, DR, Laversanne M, Alvarez CS, et al. International trends in hepatocellular carcinoma incidence. International Journal of Cancer. 2020;147(2):317–330. Available from: https://doi.org/10.1002/ijc.32723
  3. Ahiwale RJ, Chellampillai B, Pawar AP. Investigation of novel sorafenib tosylate loaded biomaterial based nano-cochleates dispersion system for treatment of hepatocellular carcinoma. Journal of Dispersion Science and Technology . 2022;43(10):1568–1586 . Available from: https://doi.org/10.1080/01932691.2021.1878034
  4. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–2576. Available from: https://doi.org/10.1053/j.gastro.2007.04.061
  5. Keating GM. Sorafenib: A Review in Hepatocellular Carcinoma. Targeted Oncology. 2017;12(2):243–253. Available from: https://dx.doi.org/10.1007/s11523-017-0484-7
  6. Villarroel MC, Pratz KW, Xu L, Wright JJ, Smith BD, Rudek MA. Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients. Investigational New Drugs. 2012;30(6):2096–2102. Available from: https://dx.doi.org/10.1007/s10637-011-9767-5
  7. Das SS, Verma PRP, Singh SK. Quercetin-Loaded Nanomedicine as Nutritional Application. Nanomedicine for Bioactives. 2020;p. 259–301. Available from: https://doi.org/10.1007/978-981-15-1664-1_9
  8. Puszkiel A, Noé G, Thomas-Schoemann A, Bellesoeur A, Boudou-Rouquette P, Vidal M, et al. Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma. International Journal of Pharmacokinetics. 2017;2(4):257–283. Available from: https://dx.doi.org/10.4155/ipk-2017-0008
  9. Kuo FC, Chen CY, Lin NC, Liu C, Hsia CY, Loong CC. Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab. Transplantation Proceedings. 2023;55(4):878–883. Available from: https://dx.doi.org/10.1016/j.transproceed.2023.03.064
  10. O'Brien T, Dolan L. Immune checkpoint inhibitors and timing of administration. The Lancet Oncology. 2022;23(2). Available from: https://dx.doi.org/10.1016/s1470-2045(21)00704-x

Copyright

© 2024 Published by Krupanidhi College of Pharmacy. This is an open-access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/) 

  • 13 October 2024

Year: 2024, Volume: 23, Issue: 3


More articles

DON'T MISS OUT!

Subscribe now for latest articles and news.